Pharmaceutical Executive January 3, 2025
Mike Hollan

GlobalData’s new findings show that the Zepbound may become the top WLM in the coming year.

For the past two years, Ozempic and Wegovy have dominated the conversation when it comes to weight-loss medications (WLMs). The two medications, developed and distributed by Novo Nordisk, have made GLP-1s a highly sought after option for people looking to lose weight. According to a new report, however, a competitor may be stealing the spotlight in 2025.

GlobaData issued a report stating that it expects Eli Lilly’s Zepbound to lead the obesity market in the coming year.1 The research firm reached its conclusion based on a recent study that suggests that Zepbound may be more effective at promoting weight loss than Wegovy. The findings...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma / Biotech, Survey / Study, Trends
Related Articles:
Moderna says it’s ‘one step closer’ to a norovirus vaccine as the virus spreads across the U.S.
Open Source in Life Sciences: Balancing Innovation and Compliance
The hidden traps of business building: A guide for life science CEOs
Report: Prices for top Medicare Part D drugs nearly doubled since entering the market
High cost of weight loss drugs drives employers to require nutrition counseling, in boost for startups

Share This Article